What is Allurion?
Allurion operates at the intersection of digital health and medical device innovation. The company is best known for the Allurion Program, a comprehensive weight-loss ecosystem that centers on the Allurion Smart Capsule, the world's first swallowable, procedureless gastric balloon. Beyond the hardware, the company provides a robust Virtual Care Suite, which includes the Allurion Mobile App for patient engagement and Allurion Insights, an AI-powered platform for healthcare providers. By integrating connected scales and data-driven analytics, Allurion offers a holistic, non-invasive alternative to traditional bariatric interventions, positioning itself as a disruptive force in the global obesity treatment market.
How much funding has Allurion raised?
Allurion has raised a total of $281.3M across 16 funding rounds:
Private Equity
$6M
Multiple Rounds
$52M
Series B
$34M
Debt
$1M
Debt
$1M
Debt
$25M
Stock Offering
$100M
Debt
$48M
Share Placement
$2.3M
Stock/Share Issuance
$5M
Private Equity (2016): $6M backed by Romulus Capital
Private Equity (2017): $19M, investors not publicly disclosed
Series C (2017): $27M led by Romulus Capital and IDO Investments
Debt (2017): $6M supported by Silicon Valley Bank
Series B (2020): $34M featuring Bridge Bank, Novalis LifeSciences, IDO Investments, and Romulus Capital
Debt (2020): $1M backed by PPP
Debt (2021): $1M with participation from PPP
Debt (2021): $25M led by Runway Growth Capital LLC
Stock Issuance/Offering (2023): $100M, investors not publicly disclosed
Debt (2024): $48M featuring RTW Investments
Share Placement (2024): $2.3M, investors not publicly disclosed
Stock/Share Issuance (2025): $5M, investors not publicly disclosed
Key Investors in Allurion
Romulus Capital
Romulus Capital is an early-stage venture capital firm founded in 2008, focusing on leading Seed and Series A rounds for B2B companies that disrupt traditional industries or are deep technology firms emerging from elite research groups.
IDO Investments
IDO Investments is a technology investment firm based in Oman, focused on accelerating the growth of a knowledge-based economy by investing in established growth-stage startups that offer disruptive solutions.
RTW Investments
RTW is a life sciences investment and innovation firm that focuses on biotech and medtech innovation throughout the entire lifecycle, providing both capital and scientific expertise to transformative companies.
What's next for Allurion?
With the infusion of $5M, Allurion is well-positioned to accelerate its commercial expansion and further refine its AI-driven clinical support tools. The company's strategic roadmap likely involves scaling its Virtual Care Suite to new international markets and deepening its integration with healthcare provider networks. As the firm continues to navigate the regulatory landscape for its investigational devices, the focus remains on enhancing patient outcomes through data-backed, metabolically healthy weight loss protocols. This capital injection provides the necessary runway to sustain long-term growth and solidify its competitive advantage in the medtech landscape.
See full Allurion company page
